Abstract
Arterial hypertension and visceral fat accumulation constitute the most common risk factors in Czech patients with metabolic syndrome (MS). Insulin resistance, increased central sympathetic activity and reduced adrenal activity are the main pathophysiological mechanisms of hypertension development in patients with MS or type 2 diabetes.That is why ACE inhibitors or sartans are considered as the 1st choice drugs in monotherapy or in combination with other antihypertensives.
Healthy life style and complex approach to all participating risk factors represent the most important method of therapy in patients with MS.